A Study of Ramucirumab (LY3009806) or Merestinib (LY2801653) in Advanced or Metastatic Biliary Tract Cancer

ClinicalTrials.gov ID: NCT02711553

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT02711553. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Nov 12, 2026, 4:59 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Randomized, Double-Blind, Phase 2 Study of Ramucirumab or Merestinib or Placebo Plus Cisplatin and Gemcitabine as First-Line Treatment in Patients With Advanced or Metastatic Biliary Tract Cancer

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The main purpose of this study is to evaluate the efficacy and safety of ramucirumab or merestinib or placebo plus cisplatin and gemcitabine in participants with advanced or metastatic biliary tract cancer.

Study identification

NCT ID: NCT02711553
Recruitment status: Active, not recruiting
Study type: Interventional
Phase: Phase 2
Lead sponsor: Eli Lilly and Company; Industry
Enrollment: 309 participants

Conditions and interventions

Conditions

Interventions

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: May 19, 2016 (Actual)
Primary completion: Feb 16, 2018 (Actual)
Completion: Dec 2026 (Estimated)
Last update posted: Jul 22, 2026

2016 – 2026

United States locations

U.S. sites: 13
U.S. states: 8
U.S. cities: 10

Facility	City	State	ZIP	Site status
The University of Arizona Cancer Center	Tucson	Arizona	85724	—
UCSF Medical Center at Mission Bay	San Francisco	California	94158	—
Georgetown University Medical Center	Washington D.C.	District of Columbia	20007	—
University of Florida School of Medicine	Gainesville	Florida	32608	—
Karmanos Cancer Institute	Detroit	Michigan	48201	—
Washington University Medical School	City of Saint Peters	Missouri	63376	—
Washington University Medical School	Creve Coeur	Missouri	63141	—
Washington University Medical School	St Louis	Missouri	63110	—
Washington University Medical School	St Louis	Missouri	63129	—
Thomas Jefferson University	Philadelphia	Pennsylvania	19107	—
Fox Chase Cancer Center	Philadelphia	Pennsylvania	19111-2497	—
Florida Cancer Specialists	Nashville	Tennessee	37203	—
Tennessee Oncology PLLC	Nashville	Tennessee	37203	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 69 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT02711553, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Jul 22, 2026 · Synced Nov 12, 2026